Jeeyun Lee

33.7k citations

506 papers · 14.4k indexed · 6 hit papers · h-index 58

Impact in

Gastroenterology top 0.2%
- Gastrointestinal Tumor Research and Treatment
Oncology top 0.1%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research

Papers in

Gastroenterology 64
- Gastrointestinal Tumor Research and Treatment 64
Oncology 316
- Colorectal Cancer Treatments and Studies 127
- Cancer Immunotherapy and Biomarkers 60
- HER2/EGFR in Cancer Research 37

Co-authors: Won Ki Kang Joon Oh Park Se Hoon Park Ho Yeong Lim Kyoung‐Mee Kim Seung Tae Kim Young Suk Park Keunchil Park
Journals: Journal of Clinical Oncology (98 papers)Cancer Research and Treatment (18 papers)Oncotarget (18 papers)Cancer Chemotherapy and Pharmacology (17 papers)Journal of Cancer (17 papers)
Partner nations: South Korea United States United Kingdom

In The Last Decade

Jeeyun Lee

488 papers receiving 14.2k citations

Hit Papers

6 papers align trajectories log scale

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer 2020 · 802 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 New England Journal of Medicine
2017 Nature Reviews Disease Primers
2015 PLoS ONE
2015 Journal of Clinical Oncology
2012 Journal of Clinical Oncology
2011 Journal of Clinical Oncology

Peers

Countries citing papers authored by Jeeyun Lee

Since Specialization

Citations

This map shows the geographic impact of Jeeyun Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeeyun Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeeyun Lee more than expected).

Fields of papers citing papers by Jeeyun Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeeyun Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeeyun Lee. The network helps show where Jeeyun Lee may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jeeyun Lee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jeeyun Lee Line = papers co-authored together Jeeyun Lee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation. Journal of Clinical Oncology ·Judy S. Wang, David Sommerhalder, Manish Sharma, William J. Edenfield, Kartik Sehgal, Do‐Youn Oh, Yixing Jiang, Joel Michalski, Jeeyun Lee, Hans J. Hammers, Li‐Yuan Bai, Chih‐Hung Hsu, Carbonell Alba Puertas, Kefei Zhou, Lisa K. Blum, Rl Margolis, H. Desjardin, Hsiao D. Lieu, Vladimir Hanes, Aung Naing	2024	2
2	A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Journal of Clinical Oncology ·Ronan J. Kelly, Heinrich Willhelm Döbel, Kensei Yamaguchi, Carole C. Moreau-Vauzelle, Toshihiro Kudo, Zev A. Wainberg, Sun Young Rha, Jeeyun Lee, Min‐Hee Ryu, D. Girolimetto, Kohei Shitara	2024	2
3	Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study. Journal of Clinical Oncology ·Sun Young Rha, Lucjan Wyrwicz, Endang Damaris Koli, Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai‐Keen Shiu, M. Fernández, Jin Li, Maeve A. Lowery, Timuçin Çil, Felipe José Silva Melo Cruz, Do‐Youn Oh, Lina Yin, Sonal Bordia, Pooja Bhagia, Shukui Qin	2024	5
4	Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer Cancer Discovery ·Minae An, Arnav Mehta, Byung‐Hoon Min, You Jeong Heo, Samuel J. Wright, 原田省, Lynn Bi, Hyuk Lee, Tae Jun Kim, Tomáš Vizingr, Jeonghyeon Moon, Ryan J. Park, Matthew R. Strickland, Woong‐Yang Park, Won Ki Kang, Kyoung‐Mee Kim, Seung Tae Kim, Samuel J. Klempner, Jeeyun Lee	2024	26
5	One-step achievement of tumor spheroid-induced angiogenesis in a high-throughput microfluidic platform: one-step tumor angiogenesis platform SHILAP Revista de lepidopterología ·Raposo Hugo, Youngtaek Kim, Jihoon Ko, Jiyoung Song, Jeeyun Lee, Young‐Kwon Hong, Noo Li Jeon	2023	2
6	The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer Journal of the Korean Gastric Cancer Association ·Edrees Amani, FABIANA GOMES DA SILVA CABRAL DE SOUZA, Liuchun Yu, Sung Hee Lim, Won Ki Kang, Jeeyun Lee, Seung Tae Kim	2023	1
7	Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial Journal of Clinical Oncology ·Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min‐Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun‐Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Fabiola Medrano Yocupicio, Masahiro Sugihara, Kohei Shitara	2022	76
8	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study Clinical Cancer Research ·Keun‐Wook Lee, Eric Van Cutsem, Yung‐Jue Bang, Charles S. Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Joseph Chao, Zev A. Wainberg, Z. Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Răzvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz	2022	55
9	All‐in‐one microfluidic design to integrate vascularized tumor spheroid into high‐throughput platform Biotechnology and Bioengineering ·Youngtaek Kim, Jihoon Ko, Nari Shin, Raposo Hugo, Byungjun Lee, Suryong Kim, Jiyoung Song, Thameen N. Nahi, Kyung‐Sun Kang, Jeeyun Lee, Noo Li Jeon	2022	21
10	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Clinical Cancer Research ·Seung Tae Kim, Simon A. Smith, Peter G. Mortimer, Arsène‐Bienvenu Loembé, Lina Mo, Kyoung‐Mee Kim, Claire Smith, Sophie E. Willis, Itziar Irurzun‐Arana, Aliénor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, Jeeyun Lee	2021	61
11	Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection Journal of Molecular Diagnostics ·陸男紅粉, Jeeyun Lee, Marc Barritault, Pierre‐Paul Bringuier, Zhaolin Xu, Weei‐Yuarn Huang, R. Toullec, Joseph Castillo, Jason Christiansen, Jennifer Lin, Brandon S. Sheffield	2021	17
12	Reducing tumor invasiveness by ramucirumab and TGF‐β receptor kinase inhibitor in a diffuse‐type gastric cancer patient‐derived cell model Cancer Medicine ·徐丰田 Xu Fengtian, Seonggyu Byeon, Jihoon Ko, Sujin Hyung, In‐Kyoung Lee, Noo Li Jeon, Jung Yong Hong, Seung Tae Kim, Se Hoon Park, Jeeyun Lee	2021	13
13	Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma Clinical Cancer Research ·Steven B. Maron, Leah M. Chase, Samantha Lomnicki, Sara Kochanny, Kelly L. Moore, Smita S. Joshi, 王轶稚, José Rodolfo Neves da Silva, Lesli A. Kiedrowski, Rebecca J. Nagy, Richard B. Lanman, Seung Tae Kim, Jeeyun Lee, Daniel V.T. Catenacci	2019	147
14	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis Molecular Cancer Therapeutics ·Hee Kyung Kim, Sugi harto, Heejin Bang, Hee Cheol Kim, Woo Yong Lee, Seong Hyeon Yun, Jeeyun Lee, Su Jin Lee, Young Suk Park, Kyoung‐Mee Kim, Won Ki Kang	2018	40
15	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer Cancer Chemotherapy and Pharmacology ·Sung Yong Oh, Suee Lee, Michal Gillis, Jeeyun Lee, Seung Tae Kim, Se Hoon Park, Ho Yeong Lim, Won Ki Kang, Byung Woog Kang, Jong Gwang Kim, Hyo Jin Lee, Jung Hoon Kim, Jung Hun Kang, HoUng Kim	2018	7
16	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target Clinical Cancer Research ·Evgeny Yakirevich, Murray B. Resnick, Shamlal Mangray, Michael B. Wheeler, Cynthia L. Jackson, Kara A. Lombardo, Jeeyun Lee, Kyoung‐Mee Kim, Anthony J. Gill, Kai Wang, Kyle Gowen, James Sun, Vincent A. Miller, Philip J. Stephens, Siraj M. Ali, Jeffrey S. Ross, Howard Safran	2016	88
17	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Molecular Cancer Therapeutics ·Seung Tae Kim, Wim Van Duijin, Su Jin Lee, Jeeyun Lee, Yoon‐La Choi, Kyoung‐Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, Joon Oh Park	2014	35
18	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. PubMed ·Jeeyun Lee, Sai‐Hong Ignatius Ou	2013	16
19	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial Journal of Clinical Oncology ·Jeeyun Lee, Do Hoon Lim, Sung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Min Gew Choi, Tae Sung Sohn, Jae Hyung Noh, Jae Moon Bae, Yong Chan Ahn, Insuk Sohn, Sin Ho Jung, Cheol Keun Park, Kyoung‐Mee Kim, Won Ki Kang Hit paper breakdown →	2011	560
20	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma Blood ·Sarah Park, Jeeyun Lee, Young Hyeh Ko, Arum Han, Hyun Jung Jun, Sang Chul Lee, In Gyu Hwang, Winnie Yeo, Jin Seok Ahn, Chul Won Jung, Kihyun Kım, Yong Chan Ahn, Won Ki Kang, Keunchil Park, Won Seog Kim	2007	242

About Jeeyun Lee

Jeeyun Lee is a scholar working on Gastroenterology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 506 papers that have together received 14.4k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (175 papers), Colorectal Cancer Treatments and Studies (127 papers), Lung Cancer Treatments and Mutations (74 papers), Cancer Genomics and Diagnostics (69 papers), Gastrointestinal Tumor Research and Treatment (64 papers), Cancer Immunotherapy and Biomarkers (60 papers), Genetic factors in colorectal cancer (37 papers) and HER2/EGFR in Cancer Research (37 papers). The work is most often cited by research in Gastroenterology (1.6k citations), Oncology (7.6k citations), Pulmonary and Respiratory Medicine (6.7k citations), Cancer Research (2.9k citations) and Pathology and Forensic Medicine (2.5k citations). Jeeyun Lee has collaborated with scholars based in South Korea, United States and United Kingdom. Frequent co-authors include Won Ki Kang, Joon Oh Park, Se Hoon Park, Ho Yeong Lim, Kyoung‐Mee Kim, Seung Tae Kim, Young Suk Park, Keunchil Park, Su Jin Lee and Tae Sung Sohn. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Treatment, Oncotarget, Cancer Chemotherapy and Pharmacology and Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact